<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219787</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02392</org_study_id>
    <nct_id>NCT04219787</nct_id>
  </id_info>
  <brief_title>Different Limb Lengths in Gastric Bypass Surgery</brief_title>
  <acronym>SLIM</acronym>
  <official_title>Swiss Multicenter Randomized Controlled Trial on Different Limb Lengths in Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarunis - Universit채res Bauchzentrum Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarunis - Universit채res Bauchzentrum Basel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity and type 2 diabetes mellitus (T2DM) are reaching epidemic proportions in the
      developed world. In morbidly obese patients only surgical treatment (bariatric operations)
      leads to a sustained weight loss and relief of co-morbidities in the majority of patients.
      One of the most frequently performed operations is the laparoscopic proximal Roux-en-Y
      gastric bypass (LRYGB). There is still lack of knowledge why some patients respond much
      better than others to an identically performed procedure. Therefore, a number of variations
      of this operation have been introduced over the past 50 years. Increasing the length of small
      bowel being bypassed has the potential to improve the effect of the operation but buries the
      risk of nutrient deficiencies. The metabolic effect of LRYGB occurs, in part, independently
      of weight loss. The mechanisms underlying metabolic improvement through metabolic surgery are
      not yet fully understood.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excess BMI loss (%EBMIL)</measure>
    <time_frame>From baseline to 5 years after surgery.</time_frame>
    <description>The change of percent excess BMI loss (%EBMIL) after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Long Biliopancreatic Limb LRYGB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short Biliopancreatic Limb LRYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard LRYGB with a 80 cm BPL and a 180 cm long AL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Long BPL LRYGB</intervention_name>
    <description>LRYGB with an 180 cm BPL and an AL of 80 cm.</description>
    <arm_group_label>Long Biliopancreatic Limb LRYGB</arm_group_label>
    <other_name>LBPL LRYGB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Short BPL LRYGB</intervention_name>
    <description>The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.</description>
    <arm_group_label>Short Biliopancreatic Limb LRYGB</arm_group_label>
    <other_name>SBPL LRYGB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients with BMI of 35 kg/m2 or higher who comply with the regulatory rules for
        bariatric surgery in Switzerland (SMOB guidelines)

        Exclusion Criteria:

          -  general contraindications to kind of surgery

          -  known or suspected non-compliance, drug or alcohol abuse

          -  inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders etc. of the participant

          -  participation in another study

          -  age &lt; 18 years or &gt; 65 years

          -  BMI &gt; 60 kg/m2

          -  height &lt; 145 cm

          -  CL length of &lt; 180 cm as measured intraoperatively

          -  ASA physical status classification &gt; III

          -  inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marko Kraljevic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clarunis - Universit채res Bauchzentrum Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarik Delko, MD, Senior Lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>Clarunis - Universit채res Bauchzentrum Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Bueter, MD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Zurch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph Peterli, MD, Professor</last_name>
    <phone>+41617777501</phone>
    <email>ralph.peterli@clarunis.ch</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Roux-en-Y Gastric Bypass</keyword>
  <keyword>Biliopancreatic Limb Length</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

